HSD3B1 genotype and abiraterone metabolism in patients with prostate cancer

被引：0
|
作者：
Alyamani, Mohammad [1 ]
Emamekhoo, Hamid [2 ]
Park, Sunho [1 ]
Taylor, Jennifer [1 ]
Almassi, Nima [1 ]
Upadhyay, Sunil [3 ]
Tyler, Allison [1 ]
Berk, Michael P. [1 ]
Hwang, Tae Hyun [1 ]
Grivas, Petros [1 ]
Rini, Brian [1 ]
Garcia, Jorge [1 ]
Auchus, Richard J. [3 ]
Sharifi, Nima [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
[3] Univ Michigan, Sch Med, Ann Arbor, MI USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-2572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2572
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Association between polymorphisms in HSD3B1 and UGT2B17 and prostate cancer risk
    Park, Jong Y.
    Tanner, Jean-Paul
    Sellers, Thomas A.
    Huang, Yifan
    Stevens, Colleen K.
    Dossett, Nicole
    Shankar, Ravi A.
    Zachariah, Babu
    Heysek, Randy
    Pow-Sang, Julio
    UROLOGY, 2007, 70 (02) : 374 - 379
  • [42] HSD3B1 PREFERENTIALLY UTILIZES PREGNENOLONE TO PROMOTE RESISTANCE TO ANTI-ANDROGENS IN PROSTATE CANCER
    Armstrong, Cameron
    Liu, Chengfei
    Lou, Wei
    Evans, Christopher
    Gao, Allen
    JOURNAL OF UROLOGY, 2018, 199 (04): : E368 - E369
  • [43] Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer
    Flanagan, Meghan R.
    Doody, David R.
    Voutsinas, Jenna
    Wu, Qian
    Banda, Kalyan
    Sharifi, Nima
    Li, Christopher I.
    Gadi, Vijayakrishna K.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (11) : 7194 - 7201
  • [44] Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype
    Lu, C.
    Terbuch, A.
    Dolling, D.
    Yu, J.
    Wang, H.
    Chen, Y.
    Fountain, J.
    Bertan, C.
    Sharp, A.
    Carreira, S.
    Isaacs, W. B.
    Antonarakis, E. S.
    De Bono, J. S.
    Luo, J.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1178 - 1185
  • [45] Association of HSD3B1 Genotype and Clinical Outcomes in Postmenopausal Estrogen-Receptor-Positive Breast Cancer
    Meghan R. Flanagan
    David R. Doody
    Jenna Voutsinas
    Qian Wu
    Kalyan Banda
    Nima Sharifi
    Christopher I. Li
    Vijayakrishna K. Gadi
    Annals of Surgical Oncology, 2022, 29 : 7194 - 7201
  • [46] HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study
    Hearn, Jason W. D.
    AbuAli, Ghada
    Reichard, Chad A.
    Reddy, Chandana A.
    Magi-Galluzzi, Cristina
    Chang, Kai-Hsiung
    Carlson, Rachel
    Rangel, Laureano
    Reagan, Kevin
    Davis, Brian J.
    Karnes, R. Jeff Rey
    Kohli, Manish
    Tindall, Donald
    Klein, Eric A.
    Sharifi, Nima
    LANCET ONCOLOGY, 2016, 17 (10): : 1435 - 1444
  • [47] Homozygous HSD3B1(1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean?
    Sharifi, Nima
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1103 - 1105
  • [48] HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer
    Almassi, Nima
    Reichard, Chad
    Li, Jianbo
    Russell, Carly
    Perry, Jaselle
    Ryan, Charles J.
    Friedlander, Terence
    Sharifi, Nima
    JAMA ONCOLOGY, 2018, 4 (04) : 554 - 557
  • [49] HSD3B1 mediated anti-androgen resistance in prostate cancer requires specific androgen precursors
    Armstrong, Cameron M.
    Liu, Chengfei
    Lou, Wei
    Lombard, Alan P.
    Evans, Christopher
    Gao, Allen C.
    CANCER RESEARCH, 2019, 79 (13)
  • [50] Re: HSD3B1 and Resistance to Androgen-Deprivation Therapy in Prostate Cancer: A Retrospective, Multicohort Study
    Taneja, Samir S.
    JOURNAL OF UROLOGY, 2017, 197 (01): : 150 - 150
12345